Comparative Study of Terlipressin and Noradrenaline As Vasopressors in Patients With Acute-on-chronic Liver Failure and Septic Shock: A Randomized Controlled Trial

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2025 Feb 21

PMID 39980577

Authors

Tarana Gupta

Anjali Saini

Vaibhav Gaur

Ashank Goel

Affiliations

Soon will be listed here.

Abstract

Background: Sepsis is the most common acute insult in patients with acute-on-chronic liver failure (ACLF), and circulatory failure portends a poor prognosis in them.

Aim: This study aimed to compare terlipressin and noradrenaline as first-line vasopressors in patients with ACLF and septic shock.

Methods: This prospective, open-label, randomized controlled study was conducted from January 2021 to June 2022 at a tertiary care center. All patients presenting with ACLF as per the chronic liver failure consortium acute on chronic liver failure in cirrhosis study and septic shock were screened. Shock was defined as a mean arterial pressure (MAP) <65 mmHg/systolic blood pressure <90 mmHg. Patients with septic shock nonresponsive to crystalloids/colloids were randomized to receive terlipressin (group I) at 2.6 μg/kg/min and noradrenaline (group II) at 0.1 μg/kg/min. The primary outcome was an MAP >65 mmHg at 6 h. The secondary outcomes were 3-, 7-, 14-, and 28-day mortality, duration of hospital stay, cumulative dose of drug, and new events such as upper gastrointestinal bleed, acute kidney injury, jaundice, and hepatic encephalopathy within 28 days.

Results: A total of 70 patients were randomized to group I (n = 35) and group II (n = 35). According to per-protocol analysis, a higher number of patients achieved an MAP > 65 mmHg at 6 h in group II (n = 23/31, 74%) than in group I (5/34, 14%) ( < 0.001). The 3-and 7-day mortality was significantly higher in group I than in group II, with no difference at 14 and 28 days. The 28-day mortality was highest in ACLF grade-3 in both group II (22/25, 88%) and group I (15/20, 75%).

Conclusion: Terlipressin did not prove to be noninferior to norepinephrine, and therefore, norepinephrine should be the first-line vasopressor in ACLF patients with septic shock. The mortality rate was highest in ACLF grade-3 patients in both the groups, irrespective of the initial response to vasopressors. This indicates that holistic management of these patients is most important.

References

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J . Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144(7):1426-37, 1437.e1-9. DOI: 10.1053/j.gastro.2013.02.042. View

Biggins S, Angeli P, Garcia-Tsao G, Gines P, Ling S, Nadim M . Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021; 74(2):1014-1048. DOI: 10.1002/hep.31884. View

Schulz K, Altman D, Moher D . [CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials (Chinese version)]. Zhong Xi Yi Jie He Xue Bao. 2010; 8(7):604-12. DOI: 10.3736/jcim20100702. View

Wong F, Piano S, Singh V, Bartoletti M, Maiwall R, Alessandria C . Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. J Hepatol. 2020; 74(2):330-339. DOI: 10.1016/j.jhep.2020.07.046. View

Choudhury A, Kedarisetty C, Vashishtha C, Saini D, Kumar S, Maiwall R . A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int. 2016; 37(4):552-561. DOI: 10.1111/liv.13252. View

Patel B, Chittock D, Russell J, Walley K . Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002; 96(3):576-82. DOI: 10.1097/00000542-200203000-00011. View

Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T . Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol. 2009; 24(11):1791-7. DOI: 10.1111/j.1440-1746.2009.05873.x. View

Plessier A, Denninger M, Consigny Y, Pessione F, Francoz C, Durand F . Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int. 2004; 23(6):440-8. DOI: 10.1111/j.1478-3231.2003.00870.x. View

Angus D, van der Poll T . Severe sepsis and septic shock. N Engl J Med. 2013; 369(9):840-51. DOI: 10.1056/NEJMra1208623. View

10.

Lee S, Marty J, Mantz J, Samain E, Braillon A, Lebrec D . Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology. 1990; 12(3 Pt 1):481-5. DOI: 10.1002/hep.1840120306. View

11.

Arroyo V, Moreau R, Kamath P, Jalan R, Gines P, Nevens F . Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers. 2016; 2:16041. DOI: 10.1038/nrdp.2016.41. View

12.

Russell J, Walley K, Singer J, Gordon A, Hebert P, Cooper D . Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008; 358(9):877-87. DOI: 10.1056/NEJMoa067373. View

13.

Parker M, McCarthy K, Ognibene F, Parrillo J . Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest. 1990; 97(1):126-31. DOI: 10.1378/chest.97.1.126. View

14.

Green J, Beyar R, Bomzon L, Finberg J, Better O . Jaundice, the circulation and the kidney. Nephron. 1984; 37(3):145-52. DOI: 10.1159/000183235. View

15.

Lumlertgul D, Boonyaprapa S, Bunnachak D, Thanachaikun N, Praisontarangkul O, Phornphutkul K . The jaundiced heart: evidence of blunted response to positive inotropic stimulation. Ren Fail. 1991; 13(1):15-22. DOI: 10.3109/08860229109022141. View

16.

Ma Z, Meddings J, Lee S . Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am J Physiol. 1994; 267(1 Pt 1):G87-93. DOI: 10.1152/ajpgi.1994.267.1.G87. View

17.

Wong F, Pappas S, Boyer T, Sanyal A, Bajaj J, Escalante S . Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome. Clin Gastroenterol Hepatol. 2016; 15(2):266-272.e1. DOI: 10.1016/j.cgh.2016.07.016. View

18.

Kiszka-Kanowitz M, Henriksen J, Hansen E, Moller S, Bendtsen F . Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol. 2004; 39(5):486-92. DOI: 10.1080/00365520310008728. View

19.

Gustot T, Durand F, Lebrec D, Vincent J, Moreau R . Severe sepsis in cirrhosis. Hepatology. 2009; 50(6):2022-33. DOI: 10.1002/hep.23264. View

20.

Huang P, Guo Y, Li B, Liu Q . Terlipressin Versus Norepinephrine for Septic Shock: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020; 10:1492. PMC: 6936170. DOI: 10.3389/fphar.2019.01492. View